search all
browse all
Previous Next

Letter to the Chief Medical Office. Regarding waiver of 15 minute observation period post booster COVID-19 mRNA vaccine

Object Type: Asset
In Folder: Documents from 2021

Other Documents

sdb:SO|8be096a1-db1c-4619-affc-2cc2a8f9721b
32
An overview of recommendations regarding booster doses of COVID-19 vaccine for health care workers

IO_dae2fce0-6024-458a-92eb-f0d2fdaf65dc

An overview of recommendations regarding booster doses of COVID-19 vaccine for those aged 60 to 79 years

IO_d6218353-f791-40bc-a731-e70cd168914c

COVID-19 vaccination after laboratory confirmed COVID-19 infection

IO_f9c1706b-d1c2-41f1-abf5-0219dd991afc

Interim recommendations regarding booster doses of COVID-19 vaccine for those aged 80 years and older; those aged 65 and older in long term care facilities

IO_944d1122-787c-4043-a5e8-95c35457834f

Letter to the Chief Medical Office, 28th June 2021

IO_62859833-fa8c-435b-8928-7aa16540b885

Letter to the Chief Medical Office. Recommendation regarding the interval between laboratory-confirmed breakthrough infection and an additional or booster COVID-19 vaccination

IO_7c4a3a10-edf8-422d-8a8d-d5311a92cb56

Letter to the Chief Medical Office. Recommendations regarding: 1. The interval between the primary course and booster COVID-19 vaccines; 2. Booster vaccination for those with immunocompromise associated with a suboptimal response to vaccines

IO_19a68dd4-4eb1-4b99-93a4-79f32015a315

Letter to the Chief Medical Office. Regarding COVID-19 vaccine related issues under consideration

IO_1c51eb82-01bd-436a-8983-1780e7222602

Letter to the Chief Medical Office. Regarding the letter dated 15.01.21 on Notifications to Norwegian Health Authorities relating to the possible impact of COVID-19 mRNA vaccines on mortality in the frail elderly

IO_cefb488f-72eb-492c-8022-d1d2cf31c5a6

Letter to the Chief Medical Office. Regarding waiver of 15 minute observation period post booster COVID-19 mRNA vaccine

IO_897ca0f7-bdfc-4bb8-809e-03f9ff723df6

Letter to the Chief Medical Office. Regarding: 1. NIAC Recommendations re COVID-19 Vaccination after laboratory confirmed COVID-19 infection; 2. NIAC Recommendations re COVID-19 vaccination

IO_c0998e90-81a7-42a5-8f42-4260ace4edf9

Position statement: healthcare workers and COVID-19 vaccination

IO_236be0a9-8766-4c43-abd4-797c32f3b6df

Recommendations COVID-19 vaccination for those aged 12-15 years

IO_bf69ed5b-ff56-4dd9-80e9-8a72a46d67df

Recommendations COVID-19 vaccination in pregnancy

IO_0ebb8909-d948-42b9-8c40-c58f5634831a

Recommendations for the COVID-19 vaccination programme for those aged 65-69 years

IO_ffb35d60-d153-4526-81ea-131d3470c5ce

Recommendations for the role of COVID-19 heterologous vaccination in the national programme

IO_defc4d72-5d6d-4371-8d18-1ab5185b1d8c

Recommendations for the second COVID-19 vaccine dose for those who have already had a first dose of Vaxzevria®

IO_f5a9d388-9d8f-4e32-b7bf-ce9f55e2adbb

Recommendations for the use of COVID-19 vaccine Astrazeneca®

IO_a9463618-4cb3-42e9-8317-5225fe758cee

Recommendations for the use of COVID-19 vaccine Astrazeneca® in Ireland.1. In older people. 2. Dosing schedule

IO_6cad177b-ad52-4a5c-825a-800712e8a9cc

Recommendations for the use of covid-19 vaccines. 1. COVID-19 vaccine Janssen. 2. Vaxzevria COVID-19 vaccine astrazeneca. 3. mRNA vaccine dose interval

IO_476427bd-e2ea-4792-b11b-82f56ead0042

Recommendations for the use of Vaxzevria® COVID-19 vaccine Astrazeneca

IO_818d7264-b0ec-48d4-be52-a93552cd3a2d

Recommendations on COVID-19 vaccination for children aged 5 to 11 years

IO_f58ade13-2759-401f-b159-fec01f31afe2

Recommendations regarding adenoviral vector vaccines

IO_b2c44067-3ae9-4537-ae0b-84ece1428f82

Recommendations regarding an additional COVID-19 vaccine dose for those with immunocompromise associated with a suboptimal response to vaccines

IO_8401c9b1-5c85-4ebb-952e-d69fb76f9c25

Powered by Preservica
© Copyright 2024
©2024 Preservica